We sought to understand why (À)-cannabidiol (CBD) and (À)-cannabidiol-dimethylheptyl (CBD-DMH) exhibit distinct pharmacology, despite near identical structures.
Introduction
Compounds that target the type 1 and type 2 cannabinoid receptors (CB 1 and CB 2 receptors) have been touted as possible treatments for a wide range of conditions including addiction, anxiety, depression, epilepsy, neurodegenerative diseases, chronic pain, inflammation, obesity and diabetes (Ross, 2007; Pertwee, 2008; Piscitelli et al., 2012) . The orthosteric site of GPCRs is defined as the receptor site where the endogenous ligand binds. The majority of drugs that target GPCRs act at the orthosteric site (Christopoulos and Kenakin, 2002; Ross, 2007; Pertwee, 2008; Piscitelli et al., 2012) . Allosteric sites are defined as distinct receptor domains that modulate orthosteric ligand binding and receptor activity via changes in receptor conformation (Wootten et al., 2013; Congreve et al., 2017) . Conformational changes are integral to the function of GPCRs as GPCRs engage in allosteric interactions with other GPCRs, G proteins, βarrestins and small allosteric ligands (Christopoulos and Kenakin, 2002; Wootten et al., 2013) . Some allosteric ligands act as positive allosteric modulators (PAMs) that enhance the binding, potency and efficacy of orthosteric ligand-directed signalling, while others act as negative allosteric modulators (NAMs) that diminish the binding, potency and efficacy of orthosteric ligand-directed signalling (Christopoulos and Kenakin, 2002; Wootten et al., 2013) . The risk of adverse effects for allosteric modulators is reduced because allosteric compounds lack intrinsic agonism and can only modify the effects of endogenous or co-administered orthosteric ligands (Christopoulos and Kenakin, 2002; Wootten et al., 2013) . In the case of cannabinoid receptors, allosteric modulators may be especially useful because the psychomimetic and depressant effects of orthosteric ligands limit their potential therapeutic utility (Ignatowska-Jankowska et al., 2015; Cairns et al., 2017; Slivicki et al., 2017) .
(À)-Cannabidiol (CBD) is the second most abundant phytocannabinoid present in Cannabis (Mechoulam et al., 2007) . CBD acts as a partial agonist at CB 2 receptors (Mechoulam et al., 2007) , as well as the PPARγ (Campos et al., 2012) , 5-HT 1A receptors (Russo et al., 2005) and the transient receptor potential cation channel subfamily V member 1 (TRPV1; Campos et al., 2012) . CBD is a competitive antagonist of GPR55, which is described as a cannabinoid receptor and a lysophosphatidyl inositol receptor (Ryberg et al., 2007) . CBD can also act as a PAM of the opioid μ-and δ-receptors (Kathmann et al., 2006) . Importantly, CBD can mediate NAM and antagonistic effects at CB 1 receptors at concentrations well below the reported affinity (K i ) values of CBD at the orthosteric site of CB 1 receptors, suggesting that a high affinity CBD binding site, distinct from the orthosteric site on CB 1 receptors, exists (Pertwee et al., 2002; Thomas et al., 2007; Hayakawa et al., 2008; Laprairie et al., 2015; McPartland et al., 2015; Sabatucci et al., 2017; Straiker et al., 2018) . Given the diverse range of activities of CBD, modified synthetic CBD derivatives were synthesized as tools to elucidate the structure-activity relationship of CBD at CB 1 and CB 2 receptors. (À)-Cannabidiol-dimethylheptyl (CBD-DMH) is one such synthetic derivative of CBD (Figure 1 ) that displays partial agonist activity in vivo at CB 1 receptors and competes with CP55,940 for binding to CB 1 and CB 2 receptors. Yet the mechanism of action for this compound at CB 1 and CB 2 receptors remains unknown (Fride et al., 2005; Ben-Shabat et al., 2006) .
The aim of this study was to determine how CBD and CBD-DMH -two structurally similar compounds -can differ in their function at CB 1 and CB 2 receptors. Cell culture assays and in silico ligand docking to the newly described CB 1 receptor antagonist-bound crystal structure (CB 1 receptor-5TGZ) (Hua et al., 2016) and AM11542 agonist-bound crystal structure (CB1 receptor-5XRA) (Hua et al., 2017) of CBD and CBD-DMH were used to study how these ligands interact with, and affect signalling through, CB 1 and CB 2 receptors.
Methods

Cell culture
HEK293A cells were provided by Dr Denis Dupré (Dalhousie University, NS, Canada) and originally obtained from the American Type Culture Collection (Manassas, VI, USA). HEK293A cells were transfected with 400 ng of CB 1 receptor-GFP 2 or CB 2 receptor-GFP 2 expressing plasmid as described below, using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Burlington, ON, Canada). HEK293A cells used in this study were maintained between passage 3-12 at 37°C, 5% CO 2 in DMEM supplemented with 10% FBS and 100 U·mL À1 Pen/Strep.
HEK293A Cignal Lenti cAMP response element (HEK-CRE) reporter cells were provided by Dr Christopher J Sinal (Dalhousie University, NS, Canada). The HEK-CRE cells stably express the firefly luciferase gene driven by tandem repeat elements of the cAMP transcriptional response element (CRE) (Qiagen, Toronto, ON, Canada). Thus, luciferase activity is directly proportional to the level of cAMP/PKA pathway activation or inhibition. HEK-CRE cells used in this study were maintained at 37°C, 5% CO 2 in DMEM supplemented with 10% FBS, 100 U·mL À1 Pen/Strep and 200 μg·mL À1 puromycin.
Plasmids
Human CB 1 and CB 2 receptors, and βarrestin1 were cloned and expressed as either GFP 2 or Renilla luciferase (Rluc) fusion proteins at the C-terminus. CB 1 receptor-GFP 2 and CB 2 receptor-GFP 2 were generated using the pGFP 2 -N3 plasmid (PerkinElmer, Waltham, MA, USA) as described previously (Hudson et al., 2010) . βarrestin1-RlucII was generated using the pcDNA3.1 plasmid (Laprairie et al., 2014) . The GFP 2 -RlucII fusion plasmid was used as a positive control to calculate BRET Max , and the RlucII plasmid used as a negative control to calculate BRET Min has also been described previously (Laprairie et al., 2014) .
Figure 1
CBD derived compounds used in this study: (A) CBD; (B) CBD-DMH.
Radioligand binding
Cell membranes were harvested by scraping and centrifugation (Hua et al., 2016 (Laprairie et al., 2014) .
Data analysis and curve fitting
Data are presented as the mean ± the SEM from at least six independent experiments. No data collected were excluded from analysis. Microplate layout was by randomized block design to control for plate effects for all biochemical assays. Data recording was not blinded because of technical requirements, but data analyses were blinded for biochemical analyses. All data analysis and curve fitting was carried out using GraphPad Prism (v. 6.0). Radioligand data were fit with one site total binding (saturation data) or one site -fit K i (competition data) models. Radioligand competition data were fit with the concentration of [ 3 H]-CP55,940 at 1 nM and K D = 2.6 nM. Concentration-response curves (CRC) were fit with the non-linear regression with variable slope (four parameters), Gaddum/Schild EC 50 shift model or allosteric operational model (Equation 2) (Keov et al., 2011) . All curves are shown according to the best-fit model as determined by the R 2 value (GraphPad Prism v. 6.0). Pharmacological parameters were obtained from non-linear regression models as indicated in figures and tables. To fit data to the Gaddum/Schild EC 50 shift model, all variables were shared, and the Schild slope was constrained to 1.0. To fit data to the allosteric operational model (Equation 2), all variables were shared except for E max . Logα (potency co-operativity factor) and logβ (efficacy co-operativity factor) were constrained between 0 and 1 (Keov et al., 2011; Hudson et al., 2014) . Data in tables were determined by first fitting curves from individual experiments and then averaged (mean ± SEM) for those individual fits. Figures represent mean data, and non-linear regressions in those figures are derived from mean data. Data collection and statistical analysis were conducted in adherence to the guidelines of the British Journal of Pharmacology (Curtis et al., 2018) .
human CB 1 receptor crystal structures were selected as the best models for both CB 1 and CB 2 receptors. Whereas previous studies have chosen active (R*) and inactive (R) structures of bovine rhodopsin (1F88) (Hurst et al., 2006; Marcu et al., 2013) to model CB 1 receptors, we were able to access the crystal structure of the active and inactive conformers of CB 1 receptor (Hua et al., 2016 (Hua et al., , 2017 . The amino acid sequence of the human CB 2 receptor [Accession: NP_001832] was downloaded from GenBank (Benson et al., 2013) . Previous studies have conducted homology modelling of CB 2 receptors using different β-adrenoceptor structure templates (2RH1, 3SN6) (El Bakali et al., 2010; Kusakabe et al., 2013; Renault et al., 2013) ; in this study, 5XRA and 5TGZ were chosen because the sequence similarity and predicted secondary structure were most similar between CB 2 receptors and 5XRA and 5TGZ (human CB 1 receptor) (Hua et al., 2016 (Hua et al., , 2017 . For M Tham et al.
Org27569 (zinc35636065) were downloaded from ZINC (Irwin et al., 2012) . The ligand '.mol2' file for SR144528 was downloaded from PubChem (CID 3081335).
Homology modelling and model validation.
Three-dimensional models of human CB 1 and CB 2 receptors were generated in Swiss-MODEL from the template structures (5XRA, 5TGZ) (Arnold et al., 2006; Kiefer et al., 2009) . All settings were kept at default.
Ligand docking. Ligands were docked to model receptors using AutoDock 4.2.6 (Morris et al., 2009) by Lamarkian genetic algorithm (Hurst et al., 2006) . AutoDock uses a Monte Carlo simulated annealing algorithm to explore a defined grid within the virtual space of a protein model with a selected ligand. The ligand is used to probe the defined grid space via molecular affinity potentials in various conformations of ligand and receptor. The binding site of the models was defined using the AutoGrid program within AutoDock, and the grid box was set to dimensions of 35 × 35 × 35 Å in order to include the entire extracellular surface and transmembrane regions of the model receptors. The rigidity parameters were set for the receptor, and the ligands were kept flexible. All other parameters were set to default. The AutoDock algorithm AutoDock Vina 1.1.2 (Morris et al., 2009; Trott and Olson, 2010) was used to fit the ligand to the template. The best conformation for each ligand-receptor is based on lowest binding energy among eight bioactive conformations generated by eight repeated program iterations.
Materials
CP55,940, Org27569, SR144528 and (À)-CBD were purchased from Tocris Bioscience (Bristol, UK). THC was purchased from Sigma-Aldrich (Mississauga, ON, Canada). CP55,940 is a commonly used reference compound to study cannabinoid receptor signalling (Pertwee, 2008) . CP55,940 is a full agonist for inducing cAMP inhibition and βarrestin recruitment by stimulating both CB 1 and CB 2 receptors (Pertwee, 2008) . (À)-CBD-DMH was synthesized and generously gifted from Dr Raphael Mechoulam (Hebrew University, Jerusalem). All compounds were dissolved in DMSO (final concentration of 0.1% in assay media for all assays) and added directly to the media at the concentrations and times indicated. All experimental protocols and design were conducted in adherence to the guidelines of the British Journal of Pharmacology (Curtis et al., 2018) .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
The effect of CBD and CBD-DMH at CB 1 receptors
The effect of CBD and CBD-DMH on CB 1 receptordependent CRE inhibition was measured in HEK-CRE cells expressing CB 1 receptor-GFP 2 and treated with 10 μM forskolin and 1 nM-10 μM CP55,940 ± 1 nM-10 μM CBD or CBD-DMH (Figure 2A-C) . CBD reduced orthosteric ligand potency and efficacy (hereafter referred to as α and β, respectively) with an estimated K B of 545 nM in the presence of CP55,940 ( Figure 2A , Table 1 ). CBD displayed minimal agonist activity in the cAMP assay at 10 μM ( Figure 2C ). CBD-DMH enhanced α and β of CP55,940 with an estimated K B of 121 nM ( Figure 2B , Table 1 ). CBD-DMH was a partial agonist in the cAMP assay ( Figure 2C ). Therefore, CBD displayed activity consistent with the effects of a NAM of CB 1 receptor-dependent CRE inhibition. In contrast, CBD- DMH displayed activity consistent with both an agonist and PAM (i.e. ago-PAM) for CB 1 receptor-dependent CRE inhibition. βarrestin1 recruitment to CB 1 receptors was measured using BRET 2 in HEK293A cells expressing βarrestin1-Rluc and CB 1 receptor-GFP 2 and treated with 1 nM-10 μM CP55940 ± 1 nM-10 μM CBD or CBD-DMH ( Figure 2D -F). Data were analysed using the operational model of allosterism (eq. 2, Figure 2D , E). In the presence of CP55,940, CBD reduced ligand α and β with an estimated K B of 547 nM, ( Figure 2D , Table 1 ). CBD displayed no agonist activity in the BRET 2 assay at 10 μM in HEK293A cells ( Figure 2F ). CBD-DMH enhanced the α and β of CP55,940 and an estimated K B of 237 nM ( Figure 2E , Table 1 ). CBD-DMH was a partial agonist in the BRET 2 assay ( Figure 2F ).
Therefore, the activity of CBD was consistent with a NAM of CB 1 receptor-dependent βarrestin1 recruitment, whereas CBD-DMH displayed activity consistent with an ago-PAM for CB1 receptor-dependent βarrestin1 recruitment. Org27569 is a CB 1 receptor allosteric modulator that also functions as an inverse agonist of CB 1 receptors in the cAMP assay (Price et al., 2005) . We hypothesized that if CBD and CBD-DMH were allosteric modulators that interacted with the same CB 1 receptor site as Org27569, then CBD and CBD-DMH should compete with Org27569 for the allosteric binding site, producing a rightward shift in a CRE CRC and a Schild regression with slope = À1. This hypothesis assumes that Org27569, CBD and CBD-DMH share the same allosteric binding site, which has not yet been demonstrated. Org27569-dependent CRE activation was measured in HEK-CRE cells expressing CB 1 receptor-GFP 2 and treated with 1 pM-10 μM Org27569 ± 1 nM-10 μM CBD or CBD-DMH ( Figure 3A, B) . The % accumulation was calculated as described in the Methods, and data were analysed using the Gaddum/Schild EC 50 shift model ( Figure 3A, B) . CBD shifted the Org27569 CRC rightward without affecting E max ( Figure 3A , Table 2 ). CBD-DMH also produced a rightward shift in the CRC for Org27569-dependent cAMP accumulation ( Figure 3B ; Table 2 ). The observed Schild slope for CBD in the presence of Org27569 was not different from À1, whereas the Schild slope for CBD-DMH in the presence of Org27569 was ≠À1 ( Figure 3C ). CBD-dependent inhibition of Org27569 was consistent with competitive antagonism. CBD-DMH did not appear to be competitive with Org27569 at CB 1 receptors. Radioligand binding was conducted to determine the abundance of CB 1 receptors in transfected HEK293A cells and determine whether CBD and CBD-DMH competed with Figure 4B ). In silico ligand docking to CB 1 receptor-5XRA and CB 1 receptor-5TGZ was modelled in AutoDock 4.2.6. to predict and compare the possible binding sites of 2-arachidonoylglycerol (2-AG), THC, CP55,940, Org27569, CBD and CBD-DMH ( Figure 4C ). 2-AG, THC and CP55,940 interacted with a similar subset of amino acid residues in the agonist-bound (5XRA) CB 1 receptor model ( Figure 4C , Table S1 ). 2-AG, THC and CP55,940 also interacted with a similar subset of amino acid residues in the antagonist-bound (5TGZ) CB 1 receptor model, which differed from the agonist- bound model ( Figure 4C , Table S1 ). CBD interacted with a unique subset of amino acids compared to 2-AG, THC and CP55,940 in the 5TGZ model but a similar subset of amino acids in the 5XRA model ( Figure 4C , Table S1 ). CBD-DMH interacted with amino acid residues from the 2-AG/THC/ CP55,940 binding sites in the 5XRA and 5TGZ models ( Figure 4C , Table S1 ). Ligand affinity was estimated for the 5XRA-and 5TGZ-CB 1 receptor models in AutoDock 4.2.6. for 2-AG, THC, CP55,940, CBD, CBD-DMH and Org27569 (Table 3 ). The estimated K A values for 2-AG, THC, CP55,940 and Org27569 were not different from previously published data using [ 3 H]-CP55,940 in dissociated cell membranes expressing CB 1 receptors (reviewed in Pertwee, 2008) and THC or Org27569 used in this study ( Figure 4B ), which supports the predictive power of these CB 1 receptor models. The K A of CBD to the antagonist-bound CB 1 receptor (5TGZ, 146 nM), but not agonist-bound (5XRA), was similar to functional data (K B , Table 1 ). The estimated K i value for CBD in radioligand binding ( Figure 4B ) was similar to the K A of agonist-bound CB 1 receptor (5XRA, 9930 nM) ( Table 3 ). The K A values for CBD-DMH to the CB 1 receptor models (5XRA, 5TGZ) were similar to functional data (K B ; Table 1 ) and radioligand binding data (K i ; Figure 4B ).
The effect of CBD and CBD-DMH at CB 2 receptors
CB 2 receptor-dependent CRE inhibition was measured in HEK-CRE cells expressing CB 2 receptor-GFP 2 and treated with 10 μM forskolin and 1 nM-10 μM CP55940 ± 1 nM-10 μM CBD or CBD-DMH ( Figure 5A-C) . CBD treatment produced a concentration-dependent rightward shift in CP55,940-and CB 2 receptor-dependent CRE inhibition with no change in E max and an estimated affinity (K B ) of 641 nM ( Figure 5A , Table 1 ). CBD was a partial CB 2 receptor agonist ( Figure 5C ). CBD-DMH enhanced α and β of CP55,940 ( Figure 5B ). CBD-DMH displayed an estimated affinity (K B ) of 38 nM ( Figure 5B , Table 1 ). Therefore, CBD activity was consistent with orthosteric partial agonism at CB 2 receptors, whereas CBD-DMH was a PAM of CB 2 receptor-dependent CRE inhibition ( Figure 5A-C) . βarrestin1 recruitment to CB 2 receptors was measured using BRET 2 in HEK293A cells expressing βarrestin1-Rluc and CB 2 receptorR-GFP 2 and treated with 1 nM-10 μM CP55940 ± 1 nM-10 μM CBD or CBD-DMH ( Figure 5D-F) .
In the presence of CP55,940, CBD treatment produced a concentration-dependent rightward shift in CP55,940-and CB 2 receptor-dependent βarrestin1 recruitment to CB 2 receptors with an estimated K B of 420 nM ( Figure 5D , Table 1 ). CBD was a partial agonist in the BRET 2 assay at concentrations >10 μM ( Figure 5F ). CBD-DMH reduced the α and β of CP55,940 ( Figure 5E, F) . CBD-DMH displayed an estimated K B of 156 nM ( Figure 5E , F, Table 1 ). Based on these results, we concluded that CBD was an orthosteric partial agonist at CB 2 receptors, whereas CBD-DMH was a NAM of CB 2 receptor-dependent βarrestin1 recruitment.
The orthosteric ligand, SR144528, is known to act as an inverse agonist of CB 2 receptors in the cAMP assay (Portier et al., 1999) . We hypothesized that if CBD-DMH interacted with a unique receptor site compared to SR144528, then CBD-DMH should not compete with SR144528 for the allosteric binding site. This hypothesis was tested by measuring inverse agonist activity of SR144528 at CB 2 receptors in the presence of increasing concentrations of CBD-DMH. The data support the hypothesis that CBD-DMH was an allosteric compound, whereas SR144528 was an orthosteric compound because of the fit of these data to competitive versus allosteric non-linear regression models. In contrast, CBD, as a partial agonist of CB 2 receptors, should compete with SR144528 for receptor binding, producing a rightward shift in the CRC and a linear Schild regression. CB 2 receptor inverse agonistdependent CRE activation was measured in HEK-CRE cells expressing CB 2 receptor-GFP 2 and treated with 1 pM -10 μM SR144528 ± 1 nM -10 μM CBD or CBD-DMH ( Figure 6 ). CBD treatment resulted in a concentration-dependent rightward shift in SR144528-mediated CRE activation, with an estimated K B of 9.9 nM ( Figure 6A , Table 2 ). CBD-DMH increased the E max and enhanced ligand α and β of SR144528-dependent CRE activation with an estimated K B of 3.3 nM ( Figure 6B , Table 2 ). The Schild slope for CBD in the presence of SR144528 was linear but ≠1 ( Figure 6C ). The Schild slope for CBD-DMH in the presence of SR144528 was approximately 0 ( Figure 6C ). Based on these data, CBD did compete with SR144528 at CB 2 receptors but do not indicate simple one-site competition (i.e. Schild slope = 1), while CBD-DMH was a PAM of SR144528-mediated CRE activation at CB 2 receptors. 
Data are mean ± SEM of six independent experiments. Values estimated using the allosteric operational model model in GraphPad Prism v. 6.0. "-" means CRCs could not be fit to the operational model of allosterism. a Estimated using Gaddum/Schild EC 50 shift equation.
Radioligand binding was conducted to determine the abundance of CB 2 receptors in transfected HEK293A cells and determine whether CBD and CBD-DMH competed with In silico ligand docking to the 5XRA-and 5TGZ-based models of CB 2 receptors was modelled in AutoDock 4.2.6. to predict and compare the possible binding sites of 2-AG, THC, CP55,940, SR144528, CBD and CBD-DMH ( Figure 7C ). 2-AG, THC and CP55,940 all interacted with a similar subset of amino acids within the 5XRA and 5TGZ CB 2 receptor models ( Figure 7C , Table S2 Table S1 .
and A7.36 282 in the 5XRA CB 2 receptor model, CBD-DMH interacted with a unique subset of amino acid residues compared to 2-AG, THC, CP55,940 and CBD in the 5XRA and 5TGZ CB 2 receptor models ( Figure 7C , Table S2 ). Based on this model, CBD may interact with the orthosteric agonist site with a lower affinity that was not predicted in this model. For CBD-DMH, these are the predicted results based on the observation that CBD-DMH was an allosteric modulator of CP55,940-dependent signalling ( Figure 7C , Table S2 ).
Ligand affinity was estimated with the 5XRA and 5TGZ models of CB 2 receptor in AutoDock 4.2.6. for CP55,940, 2-AG, THC, CBD, CBD-DMH and SR144528 (Table 3) . The estimated K A values for CP55,940, 2-AG, THC, SR144528 and CBD were in agreement with previously published results (summarized in Pertwee, 2008) , and THC used in this study compared to the 5XRA agonist-bound model ( Figure 7B) . The CBD K i measured by [ 3 H]-CP55,940 competition ( Figure 7B ) was greater than the observed K B (Table 1) or estimated K A ( Table 3 ). The K i for CBD-DMH measured by [ 3 H]-CP55,940 competition ( Figure 7B ) was similar to the observed K B in the βarrestin1 assay (Table 1 ) and estimated K A in the modelled receptor (Table 3) . These data support the hypothesis that CBD-DMH occupied a high affinity site on CB 2 receptors separate from 2-AG, THC, CP55,940 and CBD.
Discussion
The data presented here indicate that CBD was a NAM of CB 1 receptor signalling. CBD and the known CB 1 receptor NAM Org27569 both occupied a ligand binding site in the antagonist-bound CB 1 receptor model (5TGZ) that was separate from the orthosteric agonists tested. (Hua et al., 2016 (Hua et al., , 2017 . In the agonist-bound CB 1 receptor model (5XRA), CBD interacted with a similar subset of residues to the agonists 2-AG, THC and CP55,940, albeit with a low affinity similar to that observed in [ 3 H]-CP55,940 binding assays. CBD appears to have fluid affinity for both allosteric (inactive state, R) and orthosteric (active state, R*) sites at CB 1 receptors, depending on the receptor's conformation. Based on these data, we propose that CBD has high affinity for an allosteric site in the outer vestibule of the CB 1 receptor in the inactive conformation. This hypothesis is supported by our earlier mutagenesis work with CB 1 receptors (Laprairie et al., 2015) , recent modelling of CB 1 receptor 5TGZ with CBD (Sabatucci et al., 2017) , electrophysiology data from cultural autaptic hippocampal neurons (Straiker et al., 2018) and accumulating data showing the class A GPCR outer vestibule to be a common binding region for allosteric modulators (Congreve et al., 2017) . Unlike the actions of CBD at CB 1 receptors, CBD-DMH enhanced the potency, efficacy and binding of CP55,940-dependent signalling and reduced the potency of Org27569-dependent inverse agonist activity. The reason for these differences is not clear but may have occurred because CP55,940 stabilized the active conformation of the CB 1 receptor (R*), whereas Org27569 stabilized intermediate CBD and CBD-DMH at the cannabinoid receptors (R**) or inactive (R) receptor conformations (Hurst et al., 2006; Marcu et al., 2013; Shore et al., 2014) . CBD-DMH shared common interaction residues with agonists and the allosteric modulator Org27569 in the agonist-and antagonist-bound CB 1 receptor models, suggesting these amino acids may contribute to receptor activation. Therefore, the binding site for CBD-DMH in the CB 1 receptor models bridged the allosteric and orthosteric sites. At the CB 2 receptor, CBD was an orthosteric ligand, whereas CBD-DMH was an allosteric ligand. Our data suggest that CBD binding competed, or blocked the binding of, CP55,940 and SR144528 to CB 2 receptors. The binding site and regions of CB 2 receptors that interacted with 2-AG, THC and CP55,940 in our CB 2 receptor models align with previous reports of orthosteric ligand binding at CB 2 receptors (El Bakali et al., 2010; Renault et al., 2013 (Fay and Farrens, 2013) . The allosteric activity of CBD-DMH at CB 2 receptors was pathway-specific. CBD-DMH was a PAM of CP55,940-dependent cAMP inhibition and a
Figure 5
Activity of CBD and CBD-DMH at CB 2 receptors in the presence of CP55,940. cAMP inhibition (A-C) was quantified relative to CP55,940 E max (100%) in HEK-CRE cells expressing CB 2 receptor-GFP 2 treated with 1 nM-10 μM CP55,940 ± 1 nM-10 μM CBD ( NAM of βarrestin1 recruitment. Although the exact mechanism for this was not determined, CBD-DMH may promote a conformational change in CB 2 receptors that promotes G protein-dependent signalling at the expense of βarrestin1-dependent signalling. Similarly, the CB 1 receptor allosteric modulator Org27569 has been described as a NAM of CB 1 receptor agonist-induced cAMP inhibition and a PAM of CB 1 receptor agonist-induced ERK phosphorylation (Price et al., 2005; Ahn et al., 2013; Baillie et al., 2013) . Therefore, a precedent exists for pathway-specific allostery at the cannabinoid receptors. The allosteric operational model was used to estimate ligand K B and co-operativity where data could not be fit to conventional models of receptor signalling (Keov et al., 2011; Hudson et al., 2014) . Ligand binding was also determined using conventional radioligand competition experiments (Christopoulos and Kenakin, 2002; Smith et al., 2011) . CBD reduced [
3 H]-CP55,940 binding with an apparent K i much lower than the affinity estimated in signalling assays, indicating reduced orthosteric ligand binding above 3 μM CBD and affirming higher affinity NAM signalling activity (Smith et al., 2011; Hudson et al., 2014; Congreve et al., 2017) . We observed here, and previously (Laprairie et al., 2015) , that CBD functioned as a NAM in several cell culture assays at concentrations lower than the reported concentrations at which CBD acts an orthosteric ligand of the CB 1 receptor (Thomas et al., 2007; Hayakawa et al., 2008; McPartland et al., 2015; Sabatucci et al., 2017; Straiker et al., 2018) . In contrast, CBD-DMH may enhance the binding of the orthosteric probe to a maximum and, at higher concentrations, reduce orthosteric probe binding, producing a bell-shaped curve. In the case of CB 2 receptors, CBD competitively reduced [ 3 H]-CP55,940 binding. CBD-DMH reduced orthosteric probe binding and βarrestin1 recruitment to CB 2 receptors consistent with NAM activity but enhanced CP55,940-and SR144528-dependent cAMP signalling consistent with PAM activity. The orthosteric and allosteric binding sites of both CB 1 and CB 2 receptors appear to be highly fluid and flexible. In addition, CB 1 and CB 2 receptors bind highly lipophilic and flexible ligands. The allosteric binding sites and mixed effects observed here for CBD and CBD-DMH are not without precedent: the endogenous peptide Pepcan-12 is a CB 1 receptor NAM and CB 2 receptor PAM that may bind to similar structural motifs at the cannabinoid receptors to CBD and CBD-DMH (Bauer et al., 2012; Straiker et al., 2015; Petrucci et al., 2017) . For CBD and CBD-DMH, these ligands may be capable of acting either as orthosteric agonists, allosteric modulators or a bridge between the two, depending on concentration and relative binding site affinity. Previously, fenofibrate has been described as a CB 1 receptor agonist at low concentrations and NAM at higher concentrations -demonstrating the potential of cannabinoid ligands to act through multiple mechanisms of action rather than in 'pure' agonist or allosteric roles (Priestley et al., 2015) . The N-terminal Cys98 and Cys107 contribute to the NAM activity of CBD and Org27569 (Fay and Farrens, 2013; Laprairie et al., 2015) . Sabatucci et al. (2017) recently confirmed the importance of the CB 1 receptor N-terminus for allosteric ligands -including CBD -in silico, and our findings here support their modelling. Further, the NAM activity of CBD was expanded upon in an autaptic hippocampal neuron model, suggesting it may play a role in depolarization-induced suppression of excitation (Straiker et al., 2018) . For the CB 2 receptor, it remains unknown whether the N-terminus affects ligand activity or binding (El Bakali et al., 2010) .
Figure 6
Activity of CBD and CBD-DMH at CB 2 receptors in the presence of SR144528. cAMP accumulation was quantified relative to 10 μM forskolin (100%) in HEK-CRE cells expressing CB 2 receptor-GFP 2 treated with 1 nM-10 μM CBD (A) or CBD-DMH (B) ± 1 pM-10 μM SR144528 for 4 h. 
